Management of Atopic Dermatitis in Children: A Pediatrician State of the Art by Vujnović, Sanela Domuz & Domuz, Adrijana
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Management of Atopic Dermatitis in Children: A
Pediatrician State of the Art
Sanela Domuz Vujnović and Adrijana Domuz
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.76227
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
l    j i   rij  
dditional infor ation is available at the end of the chapter
Abstract
Atopic dermatitis (AD) is one of the most common skin conditions in children and adoles-
cents. This disease is characterized by acute and chronic lesions. Acute lesions can occur 
at any age and have a recurring character. Localization of acute lesions is a characteristic 
for a certain age of the child. Chronic lesions are present after the second year of life and 
characterized by pruritus and lichenification. Ichthyosis and xerosis are also characteris-
tics of chronic lesions. The authors represent two hypotheses about pathophysiology of 
atopic dermatitis: “inside-out” hypothesis suggests that pathophysiological process is 
the result of an inflammatory response, while the “outside-inside” hypothesis suggests 
that changes of the epidermal barrier are responsible for the process in lesions in atopic 
dermatitis. There is no gold standard, clinical or laboratory, for the diagnosis of atopic 
dermatitis. The diagnosis should be based on anamnesis, clinical features and labora-
tory results. The therapeutic approach includes general and specific measures. General 
measures including topical moisturizers, bathing and bathing practices and wet-wrap 
therapy. Specific measures include topical corticosteroids and topical calcineurin inhibi-
tors. Systemic immunosuppressant agents and phototherapy are a second-line treatment 
and used when the atopic dermatitis is not controlled. These patients must be treated by 
a dermatologist or pediatricians.
Keywords: atopic dermatitis, children, corticosteroids, emollients, topical moisturizers, 
skin care, eczema
1. Introduction
Atopic dermatitis (AD) is one of the most common skin conditions in children and adoles-
cents. This disease is characterized by chronic eczematous and itchy lesions with typical 
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distributions, and relapsing [1, 2]. Atopic dermatitis has a tendency to spontaneous with-
drawal, so the incidence of this disease diminished with increasing age. The basic patho-
physiological features of this disease are an epidermal barrier dysfunction and an altered 
immunoallergic profile [3]. Firsthand contact due to their symptoms, these patients have with 
the primary healthcare team, most often pediatricians and general practitioners. The diag-
nosis of atopic dermatitis can be defined with standardized clinical criteria and scoring sys-
tems [4]. It is important to notice that this disorder can be a major therapeutic challenge for 
the physician and patient, especially intense and incessant itching. The therapeutic approach 
includes general and specific measures. General measures include topical moisturizers, bath-
ing and bathing practices and wet-wrap therapy. Children more likely have food-induced 
exacerbations. If a specific food is suspected to cause an exacerbation of atopic dermatitis, cer-
tain dietary interventions can be used. Specific measures include topical corticosteroids and 
topical calcineurin inhibitors. Systemic immunosuppressant agents and phototherapy are a 
second-line treatment and used when the atopic dermatitis is not controlled. These patients 
must be treated by a dermatologist or pediatricians.
2. Pathophysiology of atopic dermatitis
The lack of filaggrin plays an important role in the pathophysiology of atopic dermatitis. The 
large polyprotein profilaggrin degraded to produce monomeric filaggrin in the stratum corneum 
of the skin. Profilaggrin and filaggrin contribute to the structure of the epidermis and the 
functional barrier (profilaggrin and filaggrin each make different contributions to epidermal 
structure and barrier function) [5].
Filaggrins with intermediate filaments form solid connections in cornified leyers contributing 
to formation of a water loss barrier, maintaining epidermal hydration and form so-called “nat-
ural moisturizing factor” [5, 6]. Beside damaged skin barrier, in the pathophysiology of atopic 
dermatitis, numerous cells of innate and adaptive immune cells are involved. Keratinocytes 
in typical lesions release a large amount of several different proinflammatory cytokines, che-
mokines, and high levels of TSLP (thymic stromal lipoprotein) which promote Th2 immune 
response [7]. The Th2 immune response releases a large number of cytokines (IL-4, IL-13, 
IL-25, IL-33), which cause keratinocyte dysfunction and secondary changes in epidermal bar-
rier. The authors state that Th2 immune response contributes to downregulation of filaggrin 
expression in differentiated keratinocytes [8]. Beside the filaggrin, Th2 cytokines (IL-17, IL-22, 
IL-25 and IL-31) significantly downregulate the expression of other proteins of stratum cor-
neum like loricrin and involucrin [6, 8, 9].
There is an increased number of inflammatory cells such as T lymphocytes, dendritic cells, 
macrophages, mast cells and eosinophils in lesions characteristic for atopic dermatitis [7, 10].
Acute lesions in atopic dermatitis have a significantly higher number of Th2 cytokines (IL-4, 
IL-5, IL-13), while chronic lesions contain IL-4, IL-13, and numerous interferons of Th1 cells 
[11]. That is so-called biphasic Th cell response.
Environmental factors such as skin irritation, mechanical damage, low skin moisture and 
colonizing microorganisms also contribute to filaggrin expression changes [10].
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Keratinocytes in patients with atopic dermatitis show increased IFN-induced apoptosis [10]. 
Also, in patients with atopic dermatitis, smaller keratinocytes in lesions are verified.
Inflammatory response leads to variations in epidermal thickness and the size of corneocytes 
in stratum corneum in region specific flares and atopic dermatitis [9].
The authors represent two hypotheses about pathophysiology of atopic dermatitis: “inside-
out” hypothesis suggests that pathophysiological process is the result of an inflammatory 
response, while the “outside-inside” hypothesis suggests that changes of the epidermal bar-
rier are responsible for the process in lesions in atopic dermatitis [9].
3. Clinical features
The two basic characteristics of atopic dermatitis are [4]:
• specific localization of skin lesions with areas of the clean skin and
• chronic recurring character, with periods when there is no skin lesions at all and with peri-
ods of exacerbation of skin symptoms
First, clinical symptoms of atopic dermatitis occur during the first 6 months of life in 45% 
of children, during the first year of life in 60%, and before the age of 5 years in at least 85% of 
affected individuals [4]. But it never occurs in the first week of life [12]. The clinical pattern of 
atopic dermatitis has a characteristic age-dependent distribution and is commonly associated 
with elevated IgE, peripheral eosinophilia, Staphylococcus aureus colonization and comorbid-
ity with other allergic diseases [4, 12].
Atopic dermatitis as a chronic recurrent disease is characterized by acute and chronic lesions. 
Acute lesions predominantly occur in infants, while chronic lesions are characteristic of the 
later age [13, 14]. Acute lesions are characterized by erythematous papules or papulovesicules 
with oozing, as well as plaque and dry skin. Patients with atopic dermatitis commonly have 
different intensity of itch.
Acute lesions can occur at any age and have a recurring character. Localization of acute lesions 
is characteristic for a certain age of the child [12].
Chronic lesions are present after the second year of life and characterized by pruritus and 
lichenification. Ichthyosis and xerosis are also characteristics of chronic lesions [1, 4, 12].
Pruritus is a typical hallmark in all stages, except during the first weeks of life. Itching itself 
has different intensity and accompanied by excoriations and fibrotic nodules [1, 4].
Atopic dermatitis can cover a wide spectrum in terms of severity, ranging from very mild 
to very severe phenotypes. For severity assessment of atopic dermatitis, a diagnostic scor-
ing system such as SCORAD or ECZEMA AREA AND SEVERITY INDEX SCORES is often 
used [1, 4].
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3.1. Atopic dermatitis clinical phenotypes
Atopic dermatitis phenotypes in childhood can be divided into two groups: IgE associated 
and non-IgE associated atopic dermatitis. Group of children with IgE associated atopic der-
matitis can be with or without another allergic diseases, especially with allergic respiratory 
diseases [13, 14]. Clinical phenotypes of atopic dermatitis define according to [2, 12–14].
A. Age-related clinical pictures with age off onset
B. Diseases severity
C. Non-IgE and IgE associated form
Amat et al. in their ORCA cohort study defined three phenotypes of early onset atopic der-
matitis: infant with moderate atopic dermatitis severity and low sensitization, infant with a 
higher atopic dermatitis severity and frequent multiple sensitization and third phenotype 
children with moderate atopic dermatitis severity and moderate sensitization with parental 
familial history of asthma [15]. This phenotypic classification was used only for the epidemio-
logical study, while its use was not verified for clinical practice.
3.2. Infantile atopic dermatitis (under 2 years of age)
First symptoms of atopic dermatitis never appear in first 2 weeks of life. First symptoms com-
monly appear at the age of 3 months [1, 2, 12, 16]. Typical localization of infantile atopic 
dermatitis is cheeks with characteristic dry skin, erythema and papules with oozing. Lesions 
can form large plaques with oozing and crusts. Lesions can appear on the forehead, scalp, 
neck and extensor surface of the extremities, rarely on the trunk. The diaper area is usually 
spared. Lesions in this phase may be mild, which make it difficult to diagnose. When there are 
no erythematous lesions in typical places, the skin is dry, rough, and desquamated [1, 2, 16].
A substantial portion of patients can go into complete remission before 2 years of age [16].
3.3. Childhood atopic dermatitis (age 2–12 years)
Chronic skin lesions with lichenification and exacerbation of acute lesions are characteristic 
for atopic dermatitis in this age. Children have lichenified papules and plaques involving the 
hands, feet, wrists, ankles, periorificial areas on the head, antecubital and popliteal regions. 
Xerosis becomes dominant at this stage. These patients have a high risk of chronic illness [16].
3.4. Atopic dermatitis in adolescents (age 12–18 years)
In this period of life, the lesions are more fixed to classical areas such as the head, neck, and 
flexural areas. Lesions in the form of chronic dermatitis can also be seen on the hands [16].
3.5. Stratification based on disease severity
Atopic dermatitis covers a wide spectrum of clinical phenotypes. Most authors classify atopic 
dermatitis according to the severity of the clinical features into four groups: dry skin only, 
mild, moderate and severe atopic dermatitis. It is the best to use a valid scoring system, such 
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as SCORAD (Scoring atopic dermatitis) or Eczema Area and Severity Index Scores, for assess-
ing the severity of atopic dermatitis [16]. The most commonly used scoring system in clini-
cal practice is SCORAD, for which there is an application for Apple, Mac, PC and android 
system. This scoring system was created and validated by the European Task Force on Atopic 
Dermatitis (ETFAD) [1, 2, 16].
4. Diagnosis and trigger factors
4.1. Diagnostic criteria
It is not possible to define the gold standard for diagnosis of atopic dermatitis due to its 
heterogeneity. Diagnosis of atopic dermatitis cannot be set without skin examination [17]. 
Some diagnostic criteria developed for use in hospital, while others developed for commu-
nity settings [17]. The ISAAC proposed the full questionnaire-based protocol where a posi-
tive response to all three questions is required for the diagnosis of atopic dermatitis. These 
ISAAC diagnostic criteria are not for daily use, but for epidemiological studies became the 
gold standard.
The standard diagnostic tool in a community setting is the Hanifin and Rajka criteria [18] 
(Figure 1). Their criteria are adequate for physicians to make a diagnosis of atopic dermati-
tis. The diagnosis of atopic dermatitis by Hanifin and Rajka criteria requires the existence at 
least three major characteristics and at least three minor characteristics [1, 12, 18]. Some other 
atopic dermatitis diagnostic criteria are more practical for use in a hospital setting such as UK 
criteria and American Academy of Dermatology (AAD) criteria.
Figure 1. Diagnostic criteria by Hanifin and Rajka [18].
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It is very important to use well-defined diagnostic criteria for the diagnosis of atopic derma-
titis, especially for those patients who lack the typical phenotype of the disease [4]. Using 
visible eczema as the only criterion may lead to overdiagnosis of the disease [4].
The following diagnostic algorithm should be applied:
1. Clinical diagnosis based on well-defined diagnostic criteria
2. Patient medical history
3. Positive family history of atopic diseases
4. Blood tests (total IgE, specific IgE)
5. Specific skin test (prick test, prick to prick test, patch test)
6. Exacerbating factors or common triggers in atopic dermatitis
7. Challenge tests
Some facts about the diagnosis of atopic dermatitis should be emphasized:
• the atopy patch test is primarily a way to investigate the mechanisms of eczema
• sensitization can be detected by prick or patch tests or by measuring specific IgE antibodies 
in the blood
• the decision to make a challenge test should be individualized for each patient
• during the challenge test, children should be supervised for 48 h. In the case of a negative 
test, it is necessary to examine the child’s skin after 24 h [12].
There is no gold standard, clinical or laboratory, for the diagnosis of atopic dermatitis. 
Diagnosis should be based on anamnesis, clinical features and laboratory results [1, 2, 12, 16].
Although Hanifin and Rajka developed the gold criteria for the clinical diagnosis of atopic 
dermatitis, in clinical practice, physician also needs to use a valid scoring system to define the 
severity of clinical features [1].
4.2. Common triggers
Atopic dermatitis exacerbations can be triggered by allergens that are inhaled, ingested or in 
direct contact with the skin. Most commonly triggers are sweat, contact allergens, aeroaller-
gens and microbial agents.
Sensitization to food allergens (cow’s milk and hen’s eggs) is associated with infantile atopic 
dermatitis and related to disease severity [4]. Exposure to aeroallergens (pets, mites, and pol-
len) has been clearly shown to increase the risk factors for atopic dermatitis and atopic der-
matitis severity [1, 4].
Children with atopic dermatitis are at high risk of allergic asthma and allergic rhinitis [4, 12].
4.3. Differential diagnosis
Differential diagnosis of atopic dermatitis is shown in Figure 2.
Corticosteroids102
5. Management
The management of atopic dermatitis presents a clinical challenge [4, 12, 20].
Some studies emphasize that the breastfeeding at least 4–6 months reduced the incidence of 
atopic dermatitis in infants, but this effect is most probably transient and last to the 3rd year 
of life [4]. Some studies on high-risk infants population demonstrate that using different par-
tially and extensively hydrolyzed casein formulas for the first 6 months of life has the capacity 
to reduce atopic dermatitis by 50% in the first year of life [21].
Management of atopic dermatitis should be adapted to the severity of the clinical manifesta-
tion of atopic dermatitis [1]. Therapeutic modalities include basic treatment of the skin, topi-
cal and systemic drug application.
Figure 2. Differential diagnosis of atopic dermatitis [1, 4, 19].
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5.1. General measures
Basic treatment [1, 22, 23] means to use a skin hydration on a regular base, avoided hot water 
during showering or bathing, and contact with water should be minimized. Synthetic or wool 
material clothes should be avoided. Also, detergents and soaps designed for sensitive skin 
should be used. Further treatment should be adapted to the disease severity. It is very impor-
tant to educate child’s parent/guardian about atopic dermatitis, and treatment challenges.
Topical treatment [1, 22] includes emollients, topical glucocorticosteroids, topical antimicro-
bial therapy, topical calcineurin inhibitors, wet-wrap therapy. A combination of two different 
topical agents can be used.
Systemic treatment [22] needs to be considered if topical treatment cannot control the severity 
of atopic dermatitis. Systemic treatment includes antihistamines, antimicrobial treatment, sys-
temic corticosteroids, Cyclosporin A, Azathioprine, and so on. In a case where the physician 
has a negative or poor therapeutic response, another specialist (dermatologist, pediatrician, 
etc.) should be involved in the diagnostic and treatment management to get optimal results.
Also, in some cases, hospitalization in centers with a multidisciplinary team approach might 
be the best option for the patient.
People with atopic dermatitis should not work in the area with high humidity, places where 
they need to wash their hands often or use stronger disinfectants/irritants [1, 22].
5.1.1. Hydration, topical moisturizers and emollients
Xerose is a leading clinical sign of atopic dermatitis. Emollient creams represent the basic 
therapy of atopic dermatitis [23]. The basic mechanism of their effect is to maintain satis-
factory skin hydration, preserve the skin barrier and reduce transdermal loss of water. It is 
recommended that they can be used daily. They can be different in composition: lotions, oils, 
creams or gels. Studies have shown that one form of emollient has no advantage over oth-
ers [22, 23]. Oily preparations usually do not contain preservatives, which has advantages in 
terms of adverse effects. Lotions contain a high concentration of water, which speeds up their 
evaporation from the skin [22, 23].
The choice of a moisture can be left to the patient, which may be associated with increased 
adherence to recommended therapy [22, 24]. Selected moistures should be effective, safe, without 
additional additives and perfumes. The efficiency of the selected moisture should be reviewed 
frequently. It can be used 2–4 times a day, which depends on the frequency of bathing/show-
ering. It is recommended to apply immediately after bathing/showering, plus 2–3 a day [23].
5.1.2. Effectiveness and application technique
Original packaging emollients should be carefully stored because of possible contamination 
with bacteria. The most practical use is the pump-dispenser because there is the smallest risk 
for contamination [1, 23].
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There is no accord in order to use the determined quantity of the applied layer and the surface 
to be covered with the emollients (the whole body surface or only the affected areas of the 
skin). The rule of fingertip unit is not generally accepted for them as for corticosteroids.
In principle, in the treatment of atopic dermatitis, a moisturizer or skin care product should 
be applied to a mild eczematous lesion or dry skin on the facial surface without applying any 
topical steroids. It is reported that twice a day, external application of a moisturizer significantly 
inhibits the relapse of inflammation of atopic dermatitis compared with the untreated group [1].
5.1.3. Wet-wrap therapy
Wet-wrap therapy is a method for administering topical corticosteroids in order to increase 
their absorption [1, 2]. It can be used on the recommendation of a specialist pediatrician or 
dermatologist. It should be applied for a short period of time (7–14 days), once daily at exclu-
sively restricted area in children with severe atopic dermatitis who did not have an adequate 
therapeutic response to conventional therapy [22].
In wet-wrap therapy, it is recommended to use low potency and extremely mild corticoste-
roid preparations [19, 22]. Some authors recommend 5–10% dilution of potency topical corti-
costeroid preparation.
The application technique: a topical corticosteroid is applied to the affected skin, which then 
covers with a wet layer of tubular bandages, a gauze or a cotton suit, then placed a second 
dry layer. The recommended duration of a wet-wrap therapy is 12 h, so it is better to apply it 
overnight [2].
5.1.4. Dietary interventions
Recent studies did not show relation between food allergies and outbreaks or exacerbations in 
atopic dermatitis in children. If parents or a child notice that child’s symptoms of atopic der-
matitis aggravated by eating some foods, a provocation test for that food should be considered. 
Studies show that this deficient nutrition did not have a positive therapeutic effect on atopic 
dermatitis in children [24].
What is certainly recommended for infants with atopic dermatitis is exclusive breastfeeding 
and later transitioning to solids foods [1, 24].
5.2. Topical corticosteroids
Topical corticosteroids represent the basic antiinflammatory, immunosuppressive and anti-
proliferative therapy in atopic dermatitis. Topical corticosteroids are categorized into four 
groups based on their potency (Table 1) [1, 2, 22, 24]. The outbreak of topical corticosteroid 
therapy should be based on the severity of the clinical picture [1]. For mild atopic dermatitis, 
we use low potency topical corticosteroid preparations, for severe atopic dermatitis we use 
high potency topical corticosteroids [22].
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Also, for areas such as face, neck, axillary and groin, it should be used a mild topical corticosteroid 
preparations. In these areas, a moderate or potent topical corticosteroid should not be used for 
more than 3–5 days [24]. Topical corticosteroids can be used once or twice a day. Start the therapy 
with a single daily application, and if there is no adequate therapeutic response, introduce twice 
daily application [1, 22, 24]. This simple therapy mode will increase patients adherence to recom-
mended therapy and reduce the fear of side effects of topical corticosteroids by parents and GPs.
The application technique: the topical corticosteroid preparations dosage according to the 
finger type unit (FTU) rule. One FTU is the amount of a cream which can be applied from the 
distal skin-crease to the tip of the index finger of an adult and represents approximately 0.5 g. 
This amount of cream is enough to cover the surface of two hand areas (hand area is surface 
you are covering with hand palm down with your fingers closed together) [2, 22]. Topical cor-
ticosteroids should be applied half an hour before or after emollient creams.
Keep in mind that children have a proportionally larger body surface compared to body 
weight, which results in a higher absorption of topical corticosteroids for the same cream 
amount compared to adults [4, 24].
There are two different approaches to choose a topical corticosteroids, one recommending 
to start therapy with low potency TCS then use moderate potency TCS (“set up approach”), 
while others recommend reverse access from moderate to low potency topical corticosteroids 
(“set down approach”). These recommendations are primarily related to mild and moderate 
atopic dermatitis [1, 2, 24].
There are two forms of TCS therapy for atopic dermatitis: proactive and reactive therapy 
[1]. Proactive therapy is defined as using of topical corticosteroids in the acute phase, with 
Table 1. Topical corticosteroids potency classification [1, 2].
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 intermittent use of topical corticosteroids and a moisturizer during the remission period. 
Reactive therapy means the using of topical corticosteroids only in case of exacerbation of 
symptoms, and using only the moisture in the remission phase [1].
5.2.1. Potency and adverse effects
Potency and adverse effects are described in Tables 1 and 2.
5.2.2. Effectiveness and application technique
A fingertip unit (FTU) is the amount of topical steroid that is squeezed out from a standard tube 
along an adult’s fingertip. It should be enough to treat an area of skin double the size of the flat 
of your hand with your fingers together. The recommended dosage will depend on what part 
of the body is being treated [2, 22, 24].
For adults, the recommended FTUs to be applied in one single dose are, for example, 1 FTU for 
hands, elbows and knees, 2.5 FTUs for the face and neck, 3 FTUs for the scalp, or 4 FTUs for a 
hand and arm together, or the buttocks [25].
The following dosages are recommended for a child aged 3–6 months: entire face and neck 1 
FTU, an entire arm and hand 1 FTU, an entire leg and foot 1.5 FTUs, the entire front of chest 
and tummy (abdomen) 1 FTU, and the entire back including buttocks 1.5 FTUs [25].
For a child aged 1–2 years, entire face and neck 1.5 FTUs, an entire arm and hand 1.5 FTUs, 
an entire leg and foot 2 FTUs, the entire front of chest and abdomen 2 FTUs, the entire back 
including buttocks 3 FTUs [25].
For a child aged 3–5 years, entire face and neck 1.5 FTUs, an entire arm and hand 2 FTUs, 
an entire leg and foot 3 FTUs, the entire front of chest and abdomen 3 FTUs, the entire back 
including buttocks 3.5 FTUs [25].
Table 2. Topical corticosteroids adverse effects [1].
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For older children aged 6–10 years, entire face and neck 2 FTUs, an entire arm and hand 2.5 
FTUs, an entire leg and foot 4.5 FTUs, the entire front of chest and abdomen 3.5 FTUs, and the 
entire back including buttocks 5 FTUs [25].
5.3. Topical calcineurin inhibitors
Topical calcineurin inhibitors are non-steroidal immunomodulatory agents. The use of topi-
cal calcineurin inhibitors preparations should be under supervision by specialist dermatologists or 
pediatricians and for short time of period.
There are three preparations available [1, 22, 24]:
(1) 0.03% tacrolimus ointment,
(2) 0.1% tacrolimus ointment and
(3) 1% pinecrolimus cream.
Tacrolimus ointment 0.03% is approved for use in children over 2 years, while at a higher 
concentration (0.1%), it can be used only in children over 16 years of age [24]. Evidence from 
clinical trials supports the safe use of topical tacrolimus 0.03% in infants and younger children 
[22]. These drugs presents the second line of therapy, and only in case of acute exacerbation 
that do not respond to TCS.
Their use is recommended for the acute phase of moderate or severe atopic dermatitis in 
sensitive areas of the skin (e.g., the face, the folds) and in areas where steroid-induced 
atrophy is present [1, 24]. Numerous studies show that different combinations of TCI and 
TCS given together have sometimes a better effect than individual treatment [22, 24]. Some 
combinations did not show an expected effect than single administration. The combination 
of preparations should be personalized for each individual patient [24]. The TCS recom-
mended to use first, and in inadequate response to therapy switched to low potent TCS 
with TCI.
The application technique: an intermittent application 2–3 times a week according to the rec-
ommendation of a specialist dermatologist or pediatrician is recommended.
Side effects: the most common side effect of TCI is a transient burning that passes after several 
days of use [1, 22, 24]. These preparations cannot be used on the skin with signs of infection 
and uneroded surface.
5.4. Antimicrobial treatments
Regular administration of systemic or topical antibiotics is not recommended in patients with 
atopic dermatitis [2, 22, 24]. In patients with atopic dermatitis, affected skin is usually colo-
nized with Staphylococcus aureus [1, 2]. Previous studies show that there is no benefit from 
using topical antibiotics, antiseptics, antibacterial soaps or antibacterial bath additives [22, 24]. 
Also, the use of these agents can cause contact dermatitis or skin colonization with multire-
sistant strains of bacteria. In children aged 6 months to 17 years with moderate/severe atopic 
dermatitis and secondary S. aureus infection, the use of diluted bleach baths twice weekly with 
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administration of intranasal mupirocin twice daily (5 days per month) is more affected. This 
treatment should be repeated for 3 months [1, 2, 22, 24].
In children with frequent skin infections with S. aureus, a nasopharyngeal culture test for whole 
family should be done due to frequent intranasal colonization with this bacterium. It should 
be noted that the regular use of moisturizer and TCS significantly reduces skin colonization 
with S. aureus [22–24].
Eczema herpeticum is a potentially life-threatening infection in children with atopic dermati-
tis. Herpes infection should always be considered in patients with painful erosions and vesi-
cles. In these patients, systemic antiviral ther`apy and supportive therapies are required [1, 2].
5.5. Systemic anti-inflammatory therapy
Oral and injectable systemic corticosteroids are not recommended for long-term treatment in 
children with atopic dermatitis because of the possible side effects [1, 2, 22]. But their use as 
short-term therapy is effective to interrupt acute exacerbation in children with severe atopic der-
matitis [22, 24]. Duration of these intermittent therapies should be between 3 days and 3 weeks.
Beclomethasone dipropionate and Flunisolide should be limited for treatment of severe atopic 
dermatitis in children with atopic dermatitis refractory to standard therapies [19, 20, 26].
Immunosuppressants, such as Cyclosporine A (6–8 weeks), Methotrexate, and Azathioprine, 
could be used in children older than 16 years with severe atopic dermatitis refractory to 
standard therapies [1, 20, 24]. Only Cyclosporine A licensed for use in clinical practice for 
the treatment of atopic dermatitis. Prescriptions and using of systemic immunosuppressive 
therapy should be supervised by a specialist pediatrician [1, 20, 22]. Recommendations for the 
use of these drugs are short durations of therapy and severe atopic dermatitis refractory to 
standard therapies. Systemic side effects always should be kept in mind.
5.6. Phototherapy
Phototherapy is a second-line therapy for severe atopic dermatitis, and administration should 
be supervised by a dermatologist [2, 24].
It represents the use of ultraviolet light (UVA or UVB). In atopic dermatitis, UVB narrowband 
and long-wave UVA are use. The phototherapy is usually applied in elderly children with 
chronic atopic dermatitis or severe atopic dermatitis or intractable severe atopic dermatitis.
5.7. Antihistamines
The use of antihistamines can be considered in older children with acute flares where there 
is significant sleep disturbance [24]. Recent studies show that administration of fexofenadine 
hydrochloride has effects in the treatment of itch and nocturnal pruritus. Application should 
be limited to 1 week [22, 24].
The use of oral antihistamines is not recommended in the treatment of atopic dermatitis [2]. 
It is recommended to use a more potent TCS in children with itch or nocturnal pruritus in a 
short period of time [1, 2, 22].
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5.8. Reasons for treatment failure
There are many reasons for tretment failure, most commonly are presented below [1, 27–30].
5.8.1. Incorrect diagnosis
Many skin conditions can present with eczema and make confusion in diagnosis, such as 
psoriasis, skin infection and impetigo, fungal skin infections, seborrheic dermatitis, drug reac-
tions, skin T cell lymphoma, and keratosis pilaris.
5.8.2. Inconvenience of patients
Some patients believe that skin lesions are results of the infectious due to poor hygiene and feel 
uncomfortable to show such lesions to the doctor. In some countries and regions, there is a stigma 
for people with skin lesions. These patients often do not have adequate therapeutic treatment.
5.8.3. Poor understanding
Patients sometimes do not clearly understand the instructions given by physician about the 
therapy and the goals of the therapy. Sometimes child’s parents believe that traditional medi-
cines are better than recommended therapy. Also, they expect a quick therapeutic effect. They 
have no understanding that the disease is a chronic character.
5.8.4. Psycho-social factors
Chronic itch and sleep deprivation can lead to anxiety and depression in patients with atopic 
dermatitis.
5.8.5. Lack of education
Inadequate drug administration is most likely a reason for treatment failure. Patients some-
times are not informed enough about the correct application of creams and ointments. Patients 
sometimes are unable to abide by a prescribed therapeutic regimen due to their daily duties. 
The higher the number of daily applications, the less the chance that the patient will take them. 
Also, instructions given to child’s parents must be appropriate to their intellectual abilities.
5.8.6. Fear of adverse drug effects and steroid phobia
Topical corticosteroid phobia is especially affecting parents of pediatric patients with atopic 
dermatitis [27]. Establishing the trust-based doctor-patient/parents relationship can help 
overcome parents’ fears about therapy [28, 30]. This fear is commonly caused by misinforma-
tion or misadvice given by friends, relatives, other parents and the media. A corticosteroid 
phobia can lead to poor patient therapy compliance.
5.8.7. Hypersensitivity reactions to treatment
Moisturizers can contain different chemicals which may cause irritation or hypersensitiv-
ity reactions. Urea containing emollients may cause stinging. Pimecrolimus cream may 
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cause erythema. Chemical stabilizers of sun topical corticosteroids can cause delayed 
hypersensitivity responses [20].
5.8.8. Economic
The cost of therapy may be more expensive than the patient expects. Also, long-term therapy 
increases the cost of treatment. This can affect the patient’s adherence to therapy.
5.8.9. Lack of bonding and communication with a doctor
The physician should empathize with the patient and parents, be aware of patient’s fears, 
anxieties and beliefs. Communication with the patient should be in language which patient 
and parents can understand. During the examination, the doctor should be patient, talk to a 
patient without haste and listen to the patient without interruption. Also, the doctor during 
the repeated visits should create a trust-based relationship with the patient.
More frequent visits to the doctor increase adherence to treatment. Studies show that shorter 
periods between physicians control increase the patient’s compliance with the recommended 
therapy. Available consultation with well-educated nurse can also improve treatment adherence.
6. Conclusion
Atopic dermatitis (AD) is one of the most common skin conditions in children and adoles-
cents. This disease is characterized by chronic eczematous and itchy lesions with typical 
distributions, and relapsing. The clinical pattern of atopic dermatitis has a characteristic age-
dependent distribution and is commonly associated with elevated IgE, peripheral eosino-
philia, Staphylococcus aureus colonization and comorbidity with other allergic diseases. There 
is no gold standard, clinical or laboratory, for the diagnosis of atopic dermatitis. Diagnosis 
should be based on anamnesis, clinical features and laboratory results.
Xerose is a leading clinical sign of atopic dermatitis; therefore, emollient creams represent the 
basic therapy of atopic dermatitis. The basic mechanism of their effect is to maintain satisfac-
tory skin hydration, preserve the skin barrier and reduce transdermal loss of water.
Topical corticosteroids represent the basic anti-inflammatory, immunosuppressive and antip-
roliferative therapy in atopic dermatitis. The outbreak of topical corticosteroid therapy should 
be based on the severity of the clinical picture. For mild atopic dermatitis, we use low potency 
topical corticosteroid preparations; for severe atopic dermatitis, we use high potency topical 
corticosteroids. There are two different approaches to choose a topical corticosteroids, one 
recommends to start therapy with low potency TCS than using moderate potency TCS (“set 
up approach”). While others recommend reverse access from moderate to low potency topical 
corticosteroids (“set down approach”). These recommendations are primarily related to mild 
and moderate atopic dermatitis.
The expectations of patients and parental expectations in children with atopic dermatitis should 
always be determined, and the specific concerns of the parents should be sought and addressed.
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AAD American Academy of Dermatology
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IL interleukins
ISAAC International Study of Asthma and Allergies in Childhood
SCORAD Scoring atopic dermatitis
TCI topical calcineurin inhibitors
TCS topical corticosteroids
TSLP thymic stromal lipoprotein
UVA ultraviolet light A
UVB ultraviolet light B
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